Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants
with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.